Hiraoka A, et al. - Among unresectable hepatocellular carcinoma patients (u-HCC) (n=84) who received tyrosine kinase inhibitor (TKI) sequential therapy, including lenvatinib, researchers assessed clinical factors associated with improved prognosis. The study sample had a median age 71 years, 63 were males [Child-Pugh score 5/6/7 = 62/21/1, tumor-node-metastasis stage of Liver Cancer Study Group of Japan 6th II/III/IVa/IVb = 12/30/5/37, Barcelona Clinic Liver Cancer stage B/C = 33:51]. A good link with overall survival was displayed by the total duration of administration with TKIs. They reported a good prognosis for the whole cohort. According to the findings, for an improved prognosis of u-HCC undergoing TKI sequential therapy, good hepatic function (modified-albumin-bilirubin grade 1/2a) at introduction of the initial TKI is needed.